Anas Younes: We are developing more than one drug for the same disease indication, so we can build future combination regimens
Anas Younes posted on LinkedIn:
”Our hematology team spent the last 3 days reviewing our disease strategy with external advisors. To make a bigger impact, we are developing more than one drug for the same disease indication, so we can build future combination regimens.
For that, we have to make choices and prioritize the combinations that are likely to be more impactful so we can accelerate their development plans. I am grateful to all who participated in these thorough reviews and discussions and shared their thoughts and ideas with our team.”
Source: Anas Younes/LinkedIn
Anas Younes is the Senior Vice President and Global Head of Hematology (Early and Late Stage) Oncology R&D at AstraZeneca. Prior to working for AstraZeneca, he was the Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, and a Professor of Medicine at the University of Texas MD Anderson Cancer Center, Houston, TX.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023